Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 7/20 | 0.75 |
| ▸ | EGFR | P00533 | 10/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
| ▸ | CCNH | P51946 | 1/20 | 0.51 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518391 | 0.85 | FLT3 (1.00) | FLT3EGFRCDK1CCNB1CCNE1 | |
| SCHEMBL4513560 | 0.82 | FLT3 (0.75) | FLT3EGFRMKNK1MKNK2CDK1 | |
| SCHEMBL4510766 | 0.77 | CDK2 (0.57) | FLT3EGFRCDK1CCNB1CCNE1 | |
| SCHEMBL28857038 | 0.75 | MKNK1 (0.64) | FLT3EGFRMKNK1MKNK2CDK1 | |
| SCHEMBL30129335 | 0.74 | MKNK2 (0.79) | EGFRMKNK1MKNK2CDK1CCNB1 | |
| SCHEMBL19540924 | 0.74 | EGFR (0.72) | EGFRMKNK1MKNK2 | |
| SCHEMBL2547336 | 0.74 | EGFR (0.71) | FLT3EGFRMKNK1MKNK2HDAC1 | |
| SCHEMBL31367926 | 0.73 | EGFR (0.72) | FLT3EGFRMKNK1MKNK2CDK2 | |
| SCHEMBL14719016 | 0.73 | EGFR (0.72) | FLT3EGFRMKNK1MKNK2CDK2 | |
| SCHEMBL14663468 | 0.73 | EGFR (0.75) | EGFRMKNK1MKNK2CDK2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | claimed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | claimed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | FLT3 91/4885EGFR 598/4885MKNK1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.